Clinical trials: Metastatic Solid Tumor Cancer
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.
- Trial name
- NCT03711058
- Testing
- Copanlisib, Nivolumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer, Advanced Solid Tumors
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors.
- Conditions
- Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC)
- Trial name
- NCT03893955
- Testing
- ABBV-927, ABBV-368, ABBV-181
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
Locally Advanced or Metastatic Solid Tumors
Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors
This is a phase I study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients with Locally Advanced or Metastatic Solid Tumors.
- Trial name
- BC3195 (NCT05957471)
- Testing
- Drug: BC3195 for Injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Solid Tumors
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
The main aim of this study is to assess how the human body of adults with advanced or metastatic solid tumors absorbs, distributes, metabolizes and excretes subasumstat following a single 1 hour infusion of subasumstat.
- Trial name
- NCT05976334
- Testing
- [14C] Subasumstat, Subasumstat
- Where
- 2 sites in Hungary
- Volunteers
- 3 people
- Sponsor
- Takeda
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic Malignant Solid Neoplasm
Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Tumors, ONE SHOT Trial
This clinical trial studies the side effects of magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT) and to see how well it works in treating patients with solid tumors that have spread from where they first…
- Trial name
- NCT07671768
- Testing
- Computed Tomography, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic and Advanced Solid Tumors
A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion
- Trial name
- NCT02452268
- Testing
- NIZ985, PDR001
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Pancreatic Neoplasms
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
- Trial name
- NCT00102752
- Testing
- Glufosfamide, Gemcitabine
- Where
- 9 sites in United States, Brazil
- Volunteers
- 47 people
- Sponsor
- Threshold Pharmaceuticals
Cancer, Solid Tumor Cancer
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies.
- Conditions
- Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate
- Trial name
- NCT07424547
- Testing
- SYS6043
- Where
- 5 sites in United States
- Volunteers
- 386 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Solid Tumors
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
This is an open-label, multicenter, dose-escalation and expansion Phase Ib clinical study of RO6958688 in combination with atezolizumab. Part I of the study is subdivided into parts IA and IB.
- Trial name
- NCT02650713
- Testing
- Atezolizumab, RO6958688
- Where
- 24 sites in United States, Canada and 5 more
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Advanced/Metastatic Solid Tumors, NSCLC
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX37 in patients with advanced/metastatic solid tumors.
- Trial name
- NCT07274813
- Testing
- HLX37
- Where
- 2 sites in China
- Volunteers
- 254 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of ribociclib and gemcitabine hydrochloride in treating patients with solid tumors that have spread to other places in the body.
- Trial name
- NCT03237390
- Testing
- Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mayo Clinic
Cancer
Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
This is an intermediate patient expanded access protocol for treatment of patients with local or metastatic solid tumors with a neoantigen synthetic long peptide vaccine.
- Trial name
- NCT06963697
- Testing
- Personalized Synthetic Long Peptide Vaccine
- Where
- United States
- Sponsor
- Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
- Trial name
- NCT06607185
- Testing
- LY4066434., Cetuximab, Nab paclitaxel
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors
The purpose of this study is to determine the tolerability of ME-143, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.
- Trial name
- NCT01401868
- Testing
- ME-143
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- MEI Pharma, Inc.
Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.
- Trial name
- NCT03565991
- Testing
- Avelumab, Talazoparib
- Where
- 100 sites in United States, Belgium and 7 more
- Volunteers
- 202 people
- Sponsor
- Pfizer
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors
RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of RX108 in patients with locally advanced or metastatic…
- Trial name
- NCT03646071
- Testing
- RX108
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- NeuPharma, Inc.
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.